Costos médicos directos de la atención médica de pacientes con cáncer de mama

BACKGROUND: The economic cost of breast cancer (BC) treatment and the increase in incidence and prevalence challenges the financial stability of any healthcare system. OBJECTIVE: Determine direct medical costs (DMC) of BC treatment and factors associated with DMC. METHODS: Partial economic evaluation in a retrospective cohort of 160 patients with a confirmed diagnosis of BC. DMC was considered from the IMSS perspective. Bootstrapping analysis was used to deal with uncertainty and generalized linear model to identify factors associated with DCM. RESULTS: The total average annual cost of BC treatment was $251,018 (CI95% 225,542-276,493) Mexican pesos. In clinical stages I was $116,123, stage II $242,132, stage III $287,946, and stage IV $358,792 pesos. In progression disease, DMC were more elevate $380,117 [CI9, vs without progression ($172,897 [CI95% 152,334-195,974]), (pπ.0001). In patients who died, DMC were ($357,579 [IC95%, 308,013-410,401]) compared to those who survived ($218,699 [IC95% 192,096-245,051]) (p < 0.0001). CONCLUSIONS: The average annual cost of CM treatment was $251,018 pesos. DMCs increase significantly as patients present more advanced stages of the disease. Factors associated with costs were age, stages II, III and the progression of BC.